Atherosclerotic plaque inflammation: The final frontier?

Canadian Journal of Cardiology

Volumn 20, Issue 6, 2004, Pages 631-634

  Aikawa, Masanori ^a   Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; BIOLOGICAL MARKER; CD40 ANTIGEN; REACTIVE OXYGEN METABOLITE;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; CYTOKINE RELEASE; DRUG MECHANISM; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPID PEROXIDATION; NONHUMAN; PATHOLOGY; PREDICTION; RISK FACTOR; SIGNAL TRANSDUCTION; STROKE; THROMBOGENICITY; ANIMAL; ARTERIOSCLEROSIS; INFLAMMATION; MACROPHAGE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; THROMBOSIS;

ANIMALS; ANTIGENS, CD40; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MACROPHAGES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; THROMBOSIS;

EID: 2942718656     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Libby P, Aikawa M, Schonbeck U. Cholesterol and atherosclerosis. Biochim Biophys Acta 2000;1529:299-309.
2. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
3. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med 2002;8:1257-62.
4. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003;92:827-39.
5. Sukhova G, Schoenbeck U, Rabkin E, et al. Evidence of increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503-9.
6. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: A novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899-904.
7. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization. Circulation 1998;97:2433-44.
8. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769-71.
9. Kaikita K, Ogawa H, Yasue H, et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol 1997;17:2232-7.
10. Aikawa M, Voglic SJ, Sugiyama S, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999;100:1215-22.
11. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol 2003;14:437-45.
12. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Circulation 2003;108:1912-6,2034-40.
13. Heinecke JW. Oxidative stress: New approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 2003;91:12A-6A.
14. Rajavashisth TB, Liao JK, Galis ZS, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999;274:11924-9.
15. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158:879-91.
16. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5.
17. Aikawa M, Sugiyama S, Hill C, et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002;106:1390-6.
18. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003;41:360-70.
19. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
20. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-7.
21. Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review. Ann Intern Med 2003;139:670-82.
22. Chang MK, Binder QJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002;99:13043-8.
23. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003;108:512-5.
24. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-9.
25. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002;277:25032-9.
26. Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CE40L and prothrombotic state in hypercholesterolemia: Effects of statin therapy. Circulation 2002;106:399-402.
27. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vivo. Circulation 2001;103:276-83.
28. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: A novel target of thiazolidinediones. Circulation 2003;107:2664-9.
29. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 2003;92:34J-41J.
30. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr, Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002;277:44147-54.
31. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003;326:1423.